Quarterly ResultMay 5, 2026, 06:12 AM
Eloxx Pharma Q1 Net Loss $3.75M; Going Concern Doubt Remains
AI Summary
Eloxx Pharmaceuticals reported a net loss of $3.75 million for Q1 2026, an increase from $1.71 million in Q1 2025, driven by higher R&D and G&A expenses. The company's cash and cash equivalents rose to $6.36 million as of March 31, 2026, following $7.03 million in financing activities, including equity issuances and debt conversion. Despite this, management expressed substantial doubt about its ability to continue as a going concern for the next twelve months.
Key Highlights
- Net loss increased to $3.75 million in Q1 2026 from $1.71 million in Q1 2025.
- Research and development expenses rose to $1.66 million from $0.51 million year-over-year.
- General and administrative expenses increased to $2.14 million from $0.71 million year-over-year.
- Cash and cash equivalents stood at $6.36 million as of March 31, 2026.
- Net cash used in operating activities was $5.45 million in Q1 2026.
- Net cash provided by financing activities was $7.03 million in Q1 2026.
- Converted $1.0 million of debt into pre-funded warrants in February 2026.
- Issued pre-funded warrants for $5.0 million (Coastlands) and $2.0 million (Domicilium).